Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Vt-1161
1. 1340593-59-0
2. Vt-1161
3. Oteseconazole [usan]
4. Vhh774w97n
5. Chembl3311228
6. (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
7. (r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol
8. 2-pyridineethanol, Alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphar)-
9. 2-pyridineethanol, Alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-, (alphar)-
10. Vivjoa
11. Oteseconazole [inn]
12. Oteseconazole (usan/inn)
13. Unii-vhh774w97n
14. Oteseconazole, (+)-
15. Oteseconazole [who-dd]
16. Schembl17113021
17. Chebi:188153
18. Bdbm50046187
19. Who 10138
20. Db13055
21. Sb17420
22. Vt-1161vt-1161
23. Hy-17643
24. Cs-0016914
25. D11785
26. D87154
27. Q27291837
28. (2r)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1h-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol
29. (alphar)-alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1h-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridineethanol
Molecular Weight | 527.4 g/mol |
---|---|
Molecular Formula | C23H16F7N5O2 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 8 |
Exact Mass | 527.11922190 g/mol |
Monoisotopic Mass | 527.11922190 g/mol |
Topological Polar Surface Area | 86 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 743 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of vulvovaginal candidiasis
J - Antiinfectives for systemic use
J02 - Antimycotics for systemic use
J02A - Antimycotics for systemic use
J02AC - Triazole and tetrazole derivatives
J02AC06 - Oteseconazole
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Oteseconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oteseconazole, including repackagers and relabelers. The FDA regulates Oteseconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oteseconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oteseconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oteseconazole supplier is an individual or a company that provides Oteseconazole active pharmaceutical ingredient (API) or Oteseconazole finished formulations upon request. The Oteseconazole suppliers may include Oteseconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Oteseconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oteseconazole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Oteseconazole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Oteseconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Oteseconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oteseconazole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Oteseconazole suppliers with NDC on PharmaCompass.
Oteseconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oteseconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oteseconazole GMP manufacturer or Oteseconazole GMP API supplier for your needs.
A Oteseconazole CoA (Certificate of Analysis) is a formal document that attests to Oteseconazole's compliance with Oteseconazole specifications and serves as a tool for batch-level quality control.
Oteseconazole CoA mostly includes findings from lab analyses of a specific batch. For each Oteseconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oteseconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Oteseconazole EP), Oteseconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oteseconazole USP).
LOOKING FOR A SUPPLIER?